NCPA responds to repeal of 1099 reporting provision
ALEXANDRIA, Va. — The National Community Pharmacists Association expressed its support of the Senate’s decision to repeal the 1099 tax reporting mandate for businesses.
The Senate announced it passed an amendment that repealed a requirement for businesses to file 1099 forms with the Internal Revenue Service beginning in 2012 any time they spend more than $600 a year with any other business. NCPA EVP and CEO Kathleen Jaeger said that the business tax provision would have shifted community pharmacies focus from "clinical to clerical."
“We applaud the Senate for this bipartisan vote to repeal the 1099 provision, because full compliance with this requirement would prove daunting for independently owned pharmacy small businesses with limited staff and financial resources," Jaeger said. "Most importantly, our patients would suffer because the pharmacists would have less time to spend with them [to provide] invaluable prescription drug services and counseling."
Chauncey Billups tapped as Vaccines for Teens spokesman
NEW YORK — Chauncey Billups, point guard for the NBA’s Denver Nuggets team, was named the latest spokesman for a national multimedia campaign designed to educate preteens, teens and their parents about the importance of vaccination against serious, potentially life-threatening diseases.
As the latest spokesman for Vaccine for Teens, Billups will be featured in a new public service announcement, which will air on NBA media and network/cable game broadcasts.
Vaccine for Teens, which launched last year, is a collaboration between NBA Cares, the Society for Adolescent Health and Medicine, and Sanofi Pasteur, the vaccines business of Sanofi-Aventis.
Study: Gardasil is effective in preventing genital warts among males
WHITEHOUSE STATION, N.J. — Merck’s vaccine for human papillomavirus is 89% effective in preventing genital warts in teenage boys and young men, according to a new study.
The phase-3 study of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) in boys and men ages 16 to 26 years was published in the Feb. 3 issue of the New England Journal of Medicine. Human papillomavirus is the cause of genital and anal warts, and infection can increase the risk of developing cancer later in life.
The Food and Drug Administration approved the vaccine for preventing anal cancer in males and females ages 9 to 26 years in December 2010, based on part of this study.